---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-099333"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2024-11-18T23:59:59+00:00"
generated_at: "2026-05-29T22:55:53.687698+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aldeyra's reproxalap NDA accepted by FDA with April 2, 2025 PDUFA; expands AbbVie option deal

## Summary
- FDA accepted resubmitted NDA for reproxalap for dry eye disease; PDUFA date April 2, 2025.
- Expanded option with AbbVie: upon exercise, AbbVie pays $100M upfront (less $6M fees) plus up to $300M milestones.
- If option exercised, profit/loss split 60% AbbVie, 40% Aldeyra; Aldeyra pre-commercial costs 60% reimbursed by AbbVie.
- Option exercise period amended to 10 business days after FDA approval of reproxalap for dry eye disease.

## SEC filing metadata
- accession: 0001213900-24-099333
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2024-11-18T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000121390024099333/0001213900-24-099333-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000121390024099333/ea0221568-8k_aldeyra.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-099333
- JSON: https://secwatch.observer/filing/0001213900-24-099333.json
- Plain text: https://secwatch.observer/filing/0001213900-24-099333.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.